Search

Home > Diabetes Discourse > Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Podcast: Diabetes Discourse
Episode:

Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Category: Science & Medicine
Duration: 00:00:00
Publish Date: 2024-04-08 04:00:00
Description: Host: Carol Wysham, MD
Guest: A. Michael Lincoff, MD

Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Total Play: 0

Some more Podcasts by ReachMD

200+ Episodes
Primary Care .. 50+     6
200+ Episodes
Focus on Neu .. 10+     3